Literature DB >> 467604

Release of plasminogen activator from normal and neoplastic endometrium.

L Svanberg, B Astedt.   

Abstract

In the medium of endometrial carcinoma cultures, anti-urokinase-reacting plasminogen activator was released in contrast to cultures of normal or hyperplastic endometrium.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 467604     DOI： 10.1007/bf01968271

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  10 in total

1.  Purification of urokinase by affinity chromatography.

Authors:  L Holmberg; B Bladh; B Astedt
Journal:  Biochim Biophys Acta       Date:  1976-08-12

2.  Purification and characterization of a cellular fibrinolytic factor associated with oncogenic transformation: the plasminogen activator from SV-40-transformed hamster cells.

Authors:  J K Christman; G Acs
Journal:  Biochim Biophys Acta       Date:  1974-03-27

3.  Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver.

Authors:  L Pickart; M M Thaler
Journal:  Nat New Biol       Date:  1973-05-16

4.  On release and synthesis of fibrinolytic activators in human organ culture.

Authors:  B Astedt; M Pandolfi
Journal:  Rev Eur Etud Clin Biol       Date:  1972-03

5.  Separation and estimation split "products" of fibrinogen and fibrin in human serum.

Authors:  J E Niléhn
Journal:  Thromb Diath Haemorrh       Date:  1967-12-31

6.  Quantitation of fibrinolytic agents released in tissue culture.

Authors:  B Astedt; M Pandolfi; I M Nilsson
Journal:  Experientia       Date:  1971-03-15

7.  Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture.

Authors:  B Astedt; L Holmberg
Journal:  Nature       Date:  1976-06-17       Impact factor: 49.962

8.  Enzymatic iodination of polypeptides with 125I to high specific activity.

Authors:  J I Thorell; B G Johansson
Journal:  Biochim Biophys Acta       Date:  1971-12-28

9.  Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study.

Authors:  M B Bernik; H C Kwaan
Journal:  J Clin Invest       Date:  1969-09       Impact factor: 14.808

10.  Properties of plasminogen activators formed by neoplastic human cell cultures.

Authors:  D B Rifkin; J N Loeb; G Moore; E Reich
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307
  10 in total
  4 in total

1.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

2.  SERPINE2, an inhibitor of plasminogen activators, is highly expressed in the human endometrium during the secretory phase.

Authors:  Robert Kuo-Kuang Lee; Chi-Chen Fan; Yuh-Ming Hwu; Chung-Hao Lu; Ming-Huei Lin; Ying-Jie Chen; Sheng-Hsiang Li
Journal:  Reprod Biol Endocrinol       Date:  2011-03-23       Impact factor: 5.211

Review 3.  The use of glycylhistidyllysine in culture systems.

Authors:  L Pickart
Journal:  In Vitro       Date:  1981-06

4.  Spatiotemporal expression of the serine protease inhibitor, SERPINE2, in the mouse placenta and uterus during the estrous cycle, pregnancy, and lactation.

Authors:  Schu-Rern Chern; Sheng-Hsiang Li; Chung-Hao Lu; Edmund I Tsuen Chen
Journal:  Reprod Biol Endocrinol       Date:  2010-10-27       Impact factor: 5.211
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.